Based on the recent promising results of the PARP inhibitor CVL218 against SARS-CoV-2 in vitro (15), we evaluated the activity of stenoparib against SARS-CoV-2, with an eye toward its use as a treatment for COVID-19. The gene discussed is PARP1; the disease is COVID-19.